Comparative Study on Covalent and Noncovalent Endogenous Albumin-Binding β-Glucuronidase-Activated SN38 Prodrugs for Antitumor Efficacy
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03096 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yingxin Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Glucuronidase, Irinotecan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Albumin-binding prodrugs have been explored to overcome the limitations of small-molecule anticancer chemotherapy agents, such as inadequate physiological and pharmaceutical compatibility, as well as rapid renal clearance. Herein, we investigated two endogenous albumin-binding prodrugs, M-g-SN38 and S-g-SN38, forming macromolecular conjugates. Both prodrugs exhibited robust stability in murine and human plasma, crucial for their therapeutic potential. Selective activation by β-glucuronidase ensures minimal toxicity in their inactive state. Notably, M-g-SN38 exhibited higher cellular uptake, a longer circulation half-life, and enhanced tumor accumulation compared to S-g-SN38, suggesting its greater potential for improved antitumor efficacy. In vivo, M-g-SN38 exhibited significant antitumor activity, leading to profound tumor reduction and, in many cases, marked depletion and complete eradication in all treated mice in the HCT116 xenograft model. Furthermore, M-g-SN38 also demonstrated pronounced antitumor efficacy in the BxPC-3 xenograft model. Together, these findings provide new insights for the development of albumin-binding prodrugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, PR China.
- Innovation Center for AI and Drug Discovery, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China.
- ATLATL Innovation Center, 1077 Zhangheng Road, Shanghai 201203, PR China.
Förderung
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
Zitieren
APA
Lu, Y., Jiang, X., Yang, B., Ding, M., Shen, Y., Jin, J., Yu, J., Lu, W., Chen, Y., & Zhu, S. (2025). Comparative Study on Covalent and Noncovalent Endogenous Albumin-Binding β-Glucuronidase-Activated SN38 Prodrugs for Antitumor Efficacy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03096
Vancouver
Lu Y, Jiang X, Yang B, Ding M, Shen Y, Jin J, et al. Comparative Study on Covalent and Noncovalent Endogenous Albumin-Binding β-Glucuronidase-Activated SN38 Prodrugs for Antitumor Efficacy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03096
BibTeX
@article{Lu2025,
author = {Lu, Yingxin and Jiang, Xing and Yang, Biyu and Ding, Mengyuan and Shen, Yanyan and Jin, Jiyu and Yu, Jiahui and Lu, Wei and Chen, Yi and Zhu, Shulei},
title = {Comparative Study on Covalent and Noncovalent Endogenous Albumin-Binding β-Glucuronidase-Activated SN38 Prodrugs for Antitumor Efficacy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03096}
}
EUVIMED